Karl Alexander Deisseroth (born November 18, 1971) is an American scientist and physician. He is the D.H. Chen Foundation Professor of Bioengineering and a professor of psychiatry and behavioral sciences at Stanford University. He is known for developing the technologies of hydrogel-tissue chemistry (e.g., CLARITY and STARmap) and optogenetics, and for applying integrated optical and genetic strategies to study normal neural circuit function and dysfunction in neurological and psychiatric illnesses. In 2019, Deisseroth was elected a member of the US National Academy of Engineering for his discoveries and control of neuronal signals underlying animal behavior in health and disease, using molecular and optical tools. He is also a member of the US National Academy of Sciences and the US National Academy of Medicine.
Education Deisseroth earned a Bachelor of Arts in biochemical sciences from Harvard University in 1992 and an MD–PhD in neuroscience from Stanford University in 1998. He completed his medical internship and psychiatry residency at Stanford University School of Medicine.
Career Deisseroth has led his laboratory at Stanford University since 2004. He serves as an attending physician at Stanford Hospital and Clinics and has been affiliated with the Howard Hughes Medical Institute (HHMI) since 2009. Between 2014 and 2019, he was a foreign adjunct professor at Sweden's Karolinska Institute. In 2021, he authored a book titled Projections: A Story of Human Emotions, published by Random House, in which he explored the origins of human emotions through personal encounters with neuropsychiatric patients.
Research Light-gated ion channels, optogenetics, and neural circuits of behavior Deisseroth named this field "optogenetics" in 2006 and followed up with the development of optogenetic technologies, leading to many applications, including in psychiatry and neurology. In 2010, the journal Nature Methods named optogenetics "Method of the Year". For developing optogenetics, Deisseroth received in 2010 the Nakasone Award; in 2013 the Lounsbery Award and the Dickson Prize in Science; in 2014 the Keio Medical Science Prize; and in 2015 the Albany Prize, Lurie Prize, Dickson Prize in Medicine, and Breakthrough Prize in Life Sciences. He also received the 2015 BBVA Foundation Frontiers of Knowledge Award in Biomedicine, jointly with Edward Boyden and Gero Miesenböck. In 2016, Deisseroth received the Massry Prize along with Peter Hegemann and Miesenböck for "optogenetics, a technology that utilizes light to control cells in living tissues". In 2016, Deisseroth and Hegemann received the Harvey Prize from Technion in Israel "for their discovery of opsin molecules, involved in sensing light in microorganisms, and their pioneering work in using these opsins to develop optogenetics". Deisseroth was then awarded Japan's highest private prize, the Kyoto Prize, in 2018, for "his discovery of optogenetics and the development of causal systems neuroscience", becoming the youngest recipient of the award to date. In 2019, Deisseroth, Hegemann, Boyden, and Miesenböck won the Warren Alpert Foundation Prize. Finally in 2020, Deisseroth received the Heineken Prize from the Royal Netherlands Academy of Arts and Sciences, "for developing optogenetics — a method to influence the activity of nerve cells with light". Deisseroth is also known for achieving insight into the light-gated ion channel pore of channelrhodopsin itself, through his team's initial high-resolution crystal structures of cation and anion-conducting channelrhodopsins and through a body of structure/function work discovering mechanisms of channelrhodopsin kinetics, ion selectivity, and color selectivity, together with his frequent collaborator Peter Hegemann. Two major prizes paid particular attention to Deisseroth's work on elucidation of the structure and function of light-gated ion channels—the 2016 Harvey Prize to Deisseroth and Hegemann for the "discovery of opsin molecules, involved in sensing light in microorganisms, and for the pioneering work in utilizing these opsins to develop optogenetics", and the 2018 Gairdner Award, which noted "his group discovered the fundamental principles of the unique channelrhodopsin proteins in molecular detail by a wide range of genomic, biophysical, electrophysiological and structural techniques with many mutants in close collaboration with Peter Hegemann"). Although the first peer-reviewed paper demonstrating activation of neurons with a channelrhodopsin was from his lab in mid-2005, Deisseroth has emphasized that many "pioneering laboratories around the world" were also working on the idea and published their papers within the following year; he cites Stefan Herlitze and Alexander Gottschalk/Georg Nagel, who published their papers in late 2005, and Hiromu Yawo and Zhuo-Hua Pan, who published their initial papers in 2006 (Pan's early observation of optical activation of retinal neurons expressing channelrhodopsin would have occurred in August 2004, according to Pan, about a month after Deisseroth's initial observation). Deisseroth has published the notebook pages from early July 2004 of his initial experiment showing light activation of neurons expressing a channelrhodopsin. Deisseroth also pointed out that an even earlier experiment had occurred and was published by Heberle and Büldt in 1994, in which functional heterologous expression of a bacteriorhodopsin for light-activated ion flow had been published in a non-neural system (yeast). Optogenetics with microbial opsins as a general technology for neuroscience was enabled only by the full development of versatile strategies for targeting opsins and light to specific cells in behaving animals by taking advantage of Cre-lox neurogenetics developed by Joe Tsien in the 1990s. Other awards:
… excerpt ends here. Continue reading the full article.
